Last reviewed · How we verify

NCT02418871

Evaluation of the FluidVision Accommodating Intraocular Lens (AIOL) With an Improved Injector System

Completed NA Last updated 21 May 2021
What this trial tests

NA trial testing FluidVision AIOL in Aphakia in 53 participants. Completed in 5 September 2018.

Timeline
13 March 2015
Primary endpoint
16 March 2016
5 September 2018

Quick facts

Lead sponsorPowerVision
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment53
Start date13 March 2015
Primary completion16 March 2016
Estimated completion5 September 2018
Sites5 locations across South Africa, Hungary

Drugs / interventions tested

Conditions studied

Sponsor

PowerVision

Who can join

50 and older, any sex, with Aphakia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the clinical outcomes of an investigational IOL in patients undergoing cataract extraction and intraocular lens implantation using an improved injector system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of FluidVision AIOL

Trials testing the same drug.

Other recruiting trials for Aphakia

Currently open trials in the same condition.

Other PowerVision trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02418871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing